# CKD Treatment Research Findings

Research agent monitoring chronic kidney disease treatment developments.

---

## How to Use This File

- New findings are added at the top
- Each finding includes: date found, title, link, brief description, relevance
- Organized by run date
- Review during check-ins or reference as needed

---

## Run: January 28, 2026

### FDA Approvals & Regulatory Updates

**[FDA Accepts Furosemide Autoinjector (Furoscix ReadyFlow) sNDA for CKD Edema Treatment](https://www.pharmacytimes.com/view/fda-accepts-furosemide-autoinjector-snda-for-treatment-of-edema-in-chronic-kidney-disease-or-chronic-heart-failure)** - Pharmacy Times
- Supplemental new drug application accepted with PDUFA target action date of July 26, 2026
- For treatment of edema in adult patients with chronic kidney disease or chronic heart failure
- **Relevance:** HIGH - Pending FDA decision, potential new delivery method for standard therapy

**[KERENDIA (Finerenone) Meets Primary Endpoint in FINE-ONE Trial](https://www.bayer.com/en/us/news-stories/kerendia-for-type-1-diabetes-and-chronic-kidney-disease)** - Bayer
- Significantly reduced urine albumin-to-creatinine ratio by 25% vs placebo in type 1 diabetes patients with CKD
- Bayer plans to submit supplemental NDA to FDA in 2026
- **Relevance:** HIGH - Expanding finerenone to type 1 diabetes population, sNDA submission planned for 2026

**[Imlifidase Under FDA Review](https://www.kidneyfund.org/kidney-health-innovations)** - American Kidney Fund
- May be available as early as summer 2026 for kidney transplant patients
- **Relevance:** MEDIUM - Transplant-specific, pending approval

### Major Clinical Trial Results

**[CONFIDENCE Trial: Finerenone with Empagliflozin in CKD and Type 2 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2410659)** - NEJM
- Combination therapy resulted in greater reductions in urinary albumin-to-creatinine ratio than monotherapy
- First evidence supporting simultaneous initiation of SGLT2 inhibitors and finerenone
- **Relevance:** HIGH - NEJM publication, establishes combination therapy approach

**[Real-World Effectiveness: Triple Therapy (Finerenone + SGLT2i + GLP-1 RA)](https://www.mdpi.com/2077-0383/14/22/8209)** - Journal of Clinical Medicine
- Adding finerenone to existing SGLT2i and GLP-1 RA therapy showed adjusted UACR reduction of 51.3% over 27 weeks
- 96% of patients achieved >50% decrease in albuminuria after 8 months with triple therapy
- **Relevance:** HIGH - Real-world data supporting aggressive combination approaches

**[Network Meta-Analysis: Triple Therapy Cardiorenal Benefits](https://pmc.ncbi.nlm.nih.gov/articles/PMC12683810/)** - PMC
- Triple therapy (SGLT2i + finerenone + RAASi) showed 46% relative risk reduction for cardiorenal composite outcome
- SGLT2i superior to incretin-based therapies and finerenone for kidney composite outcomes
- **Relevance:** HIGH - Comparative effectiveness data across treatment combinations

### New Clinical Practice Guidelines

**[KDIGO 2026 Clinical Practice Guideline for Management of Anemia in CKD](https://www.kidney-international.org/article/S0085-2538(25)00495-8/fulltext)** - Kidney International
- Published January 2026, updates 2012 guideline
- Covers diagnosis/evaluation, iron therapy, ESAs, HIF-prolyl hydroxylase inhibitors, transfusions
- Uses GRADE approach for evidence appraisal
- **Relevance:** HIGH - Major guideline update from authoritative source, immediately actionable

**[American Diabetes Association 2026 Standards of Care: CKD and Risk Management](https://diabetesjournals.org/care/article/49/Supplement_1/S246/163914/11-Chronic-Kidney-Disease-and-Risk-Management)** - Diabetes Care
- Updated standards specifically addressing CKD in diabetes population
- **Relevance:** MEDIUM - Guidelines for diabetes-related CKD management

### Behavioral Interventions & Diet Protocols

**[Lifestyle Behavior Change for CKD Prevention](https://pmc.ncbi.nlm.nih.gov/articles/PMC6830616/)** - PMC Systematic Review
- Most promising interventions combine education with persuasion, modeling, and incentivization
- Effective techniques: goal setting, feedback, monitoring, and social support
- **Relevance:** MEDIUM - Evidence-based behavioral intervention strategies

**[Medical Nutrition Therapy by Registered Dietitians](https://www.ajkd.org/article/S0272-6386(20)30726-5/fulltext)** - KDOQI Guidelines
- Sodium restriction to <2,300 mg/day for blood pressure management
- Individualized potassium intake to manage serum levels
- RDN-led MNT highly successful in achieving sodium and protein intake goals
- **Relevance:** HIGH - Evidence-based dietary protocols

**[Goal Setting to Improve Diet Quality in CKD](https://pmc.ncbi.nlm.nih.gov/articles/PMC7994896/)** - PMC
- Patient-centered goal setting facilitates dietary behavior change
- Dietitian-led telehealth combining coaching calls and text messages effective
- **Relevance:** MEDIUM - Practical implementation of dietary interventions

### Comparative Effectiveness Research

**[SGLT2i vs Finerenone vs Combination on Albuminuria](https://www.mdpi.com/2075-4418/14/13/1357)** - Diagnostics
- Real-life experience comparing treatment approaches
- Provides practical guidance on medication selection
- **Relevance:** MEDIUM - Real-world comparative data

### Summary of Key Developments

1. Major guideline update: KDIGO 2026 Anemia in CKD published
2. Finerenone expanding to type 1 diabetes (FINE-ONE trial, sNDA planned 2026)
3. Strong evidence for combination therapy (SGLT2i + finerenone) from CONFIDENCE trial
4. Real-world data supporting triple therapy approaches with substantial albuminuria reduction
5. FDA decision pending July 2026 for Furoscix ReadyFlow (furosemide autoinjector)
6. Behavioral interventions emphasizing patient-centered goal setting and multidisciplinary support

---

## Run: January 24, 2026

### New Drug Treatments

**[6 New Kidney Disease Medications Approved 2025](https://www.kidney.org/news-stories/6-new-kidney-disease-medications-approved-2025)** - National Kidney Foundation
- Semaglutide (Ozempic) approved to protect kidneys in adults with type 2 diabetes and CKD
- Voyxact (sibeprenlimab-szsi) approved for IgAN
- **Relevance:** HIGH - FDA approvals, immediately actionable

**[Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2403347)** - NEJM
- Risk of primary-outcome event was 24% lower in semaglutide group vs placebo
- **Relevance:** HIGH - NEJM peer-reviewed, major clinical trial results

**[Finerenone with Empagliflozin in CKD and Type 2 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2410659)** - NEJM
- Combination therapy led to greater reduction in urinary albumin-to-creatinine ratio than either alone
- **Relevance:** HIGH - NEJM, combination therapy breakthrough

**[Empagliflozin in Patients with Chronic Kidney Disease](https://www.nejm.org/doi/full/10.1056/NEJMoa2204233)** - NEJM
- Established efficacy data for empagliflozin
- **Relevance:** HIGH - NEJM peer-reviewed

### Active Clinical Trials (2026)

**[New trial: Ravulizumab for AKI Prevention](https://www.ox.ac.uk/news/2024-09-18-new-trial-test-potential-treatment-chronic-kidney-disease)** - University of Oxford
- Testing whether single dose prevents acute kidney injury in CKD patients having heart surgery
- **Relevance:** MEDIUM - Phase testing, promising mechanism

**[Vicadrostat (EASi-KIDNEY Trial)](https://clinicaltrials.ucsf.edu/chronic-kidney-disease)** - UCSF
- Aldosterone synthase inhibitor, evaluating clinical outcomes in CKD when combined with existing treatments
- **Relevance:** MEDIUM - Novel drug class (ASi), large trial

**Atacicept for IgAN**
- Showed 46% drop in proteinuria in recent study
- May be available as soon as 2026
- **Relevance:** MEDIUM - Promising results, specific to IgAN

### Behavioral Protocols & Dietary Interventions

**[Nutritional and Metabolic Interventions for Protein-Energy Wasting in Nondialysis CKD](https://www.mdpi.com/2072-6643/18/3/390)** - MDPI Nutrients (Published Jan 24, 2026)
- Adequate energy and protein intake remain cornerstone
- High-quality and plant-based proteins, oral nutritional supplements, ketoanalogues show benefits
- Physical exercise acts synergistically with dietary interventions
- **Relevance:** HIGH - Brand new (today), comprehensive review, actionable protocols

**[KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update](https://www.ajkd.org/article/S0272-6386(20)30726-5/fulltext)** - American Journal of Kidney Diseases
- Six primary areas: nutritional assessment, MNT, dietary protein/energy, supplementation, micronutrients, electrolytes
- Sodium <100 mmol/d (<2.3 g/d) to reduce blood pressure
- Augmenting dietary potassium intake for blood pressure control
- **Relevance:** HIGH - Evidence-based guidelines, widely adopted

**[Managing Hypertension in CKD: Role of Diet and Guidelines](https://www.mdpi.com/2077-0383/14/11/3755)**
- Sodium restriction as cornerstone
- Importance of physical activity and weight management
- **Relevance:** MEDIUM - Hypertension management in CKD context

---

